Search Results - "Harrington, K. J"

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers by Harrington, K J, Billingham, L J, Brunner, T B, Burnet, N G, Chan, C S, Hoskin, P, Mackay, R I, Maughan, T S, Macdougall, J, McKenna, W G, Nutting, C M, Oliver, A, Plummer, R, Stratford, I J, Illidge, T

Get full text

HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer) by Plowright, L, Harrington, K J, Pandha, H S, Morgan, R

“…The HOX genes are a family of homeodomain-containing transcription factors that determine the identity of cells and tissues during embryonic development. They…”
Get full text

Radiovirotherapy: principles and prospects in oncology by Touchefeu, Y, Franken, P, Harrington, K J

“…Radiovirotherapy is defined as the use of viruses to deliver radioisotopic treatment into infected cells. Oncolytic viruses are able to selectively target and…”
Get more information

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck by del Campo, J M, Hitt, R, Sebastian, P, Carracedo, C, Lokanatha, D, Bourhis, J, Temam, S, Cupissol, D, De Raucourt, D, Maroudias, N, Nutting, C M, Compton, N, Midwinter, D, Downie, L, Biswas-Baldwin, N, El-Hariry, I, Harrington, K J

“…Background: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER-2) tyrosine kinases. This study investigated the…”
Get full text

OX40 and 4-1BB delineate distinct immune profiles in sarcoma by Melake, MJ, Smith, HG, Mansfield, D, Davies, E, Dillon, MT, Wilkins, AC, Patin, EC, Pedersen, M, Buus, R, Melcher, AA, Thway, K, Miah, AB, Zaidi, SH, Hayes, AJ, Fenton, TR, Harrington, KJ, McLaughlin, M

“…Systemic relapse after radiotherapy and surgery is the major cause of disease-related mortality in sarcoma patients. Combining radiotherapy and immunotherapy…”
Get full text

Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma by Nutting, C.M., van Herpen, C.M.L., Miah, A.B., Bhide, S.A., Machiels, J.-P., Buter, J., Kelly, C., de Raucourt, D., Harrington, K.J.

“…Background: Treatment options for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) are limited with response rates to cytotoxic…”
Get full text

Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers by BHIDE, S. A, NEWBOLD, K. L, HARRINGTON, K. J, NUTTING, C. M

“…Radiotherapy and surgery are the principal curative modalities in treatment of head and neck cancer. Conventional two-dimensional and three-dimensional…”
Get full text

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial by White, C L, Twigger, K R, Vidal, L, De Bono, J S, Coffey, M, Heinemann, L, Morgan, R, Merrick, A, Errington, F, Vile, R G, Melcher, A A, Pandha, H S, Harrington, K J

“…There is an emerging realization from animal models that the immune response may have both detrimental and beneficial therapeutic effects during cancer…”
Get full text

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity by Ilett, E J, Prestwich, R J, Kottke, T, Errington, F, Thompson, J M, Harrington, K J, Pandha, H S, Coffey, M, Selby, P J, Vile, R G, Melcher, A A

“…Reovirus is a naturally occurring oncolytic virus currently in early clinical trials. However, the rapid induction of neutralizing antibodies represents a…”
Get full text

Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy by Ismail, M, Bokaee, S, Davies, J, Harrington, K J, Pandha, H

“…Aquaporins ( AQPs ) are intrinsic membrane proteins that facilitate selective water and small solute movement across the plasma membrane. In this study, we…”
Get full text

Review article: gene therapy, recent developments and future prospects in gastrointestinal oncology by Touchefeu, Y., Harrington, K. J., Galmiche, J. P., Vassaux, G.

“…Aliment Pharmacol Ther 2010; 32: 953–968 Summary Background  Gene therapy consists of the introduction of genetic material into cells for a therapeutic…”
Get full text

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma by Errington, F, White, C L, Twigger, K R, Rose, A, Scott, K, Steele, L, Ilett, L J, Prestwich, R, Pandha, H S, Coffey, M, Selby, P, Vile, R, Harrington, K J, Melcher, A A

“…Reovirus is a promising unmodified double-stranded RNA (dsRNA) anti-cancer oncolytic virus, which is thought to specifically target cells with activated Ras…”
Get full text

The effect of parotid gland‐sparing intensity‐modulated radiotherapy on salivary composition, flow rate and xerostomia measures by Richards, TM, Hurley, T, Grove, L, Harrington, KJ, Carpenter, GH, Proctor, GB, Nutting, CM

“…Objectives To describe parotid gland (PG) saliva organic and inorganic composition and flow rate changes, after curative intensity‐modulated radiotherapy…”
Get full text

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer by KIRBY, A. M, A'HERN, R. P, D'AMBROSIO, C, TANAY, M, SYRIGOS, K. N, ROGERS, S. J, BOX, C, ECCLES, S. A, NUTTING, C. M, HARRINGTON, K. L

“…To assess the level of activity and toxicity of gefitinib (ZD1839, Iressatrade mark) in a population of patients with locally recurrent and/or metastatic head…”
Get full text

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer by Simpson, G R, Horvath, A, Annels, N E, Pencavel, T, Metcalf, S, Seth, R, Peschard, P, Price, T, Coffin, R S, Mostafid, H, Melcher, A A, Harrington, K J, Pandha, H S

“…Background: There are still no effective treatments for superficial bladder cancer (SBC)/non-muscle invasive bladder cancer. Following treatment, 20% of…”
Get full text

Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer by Bhide, S A, Ahmed, M, Barbachano, Y, Newbold, K, Harrington, K J, Nutting, C M

“…We describe a retrospective series of patients with advanced head-and-neck cancer who were treated with induction chemotherapy followed by radical…”
Get full text

Oncolytic Vaccinia virus and radiotherapy in head and neck cancer by Mansfield, D, Pencavel, T, Kyula, J.N, Zaidi, S, Roulstone, V, Thway, K, Karapanagiotou, L, Khan, A.A, McLaughlin, M, Touchefeu, Y, Seth, R, Melcher, A.A, Vile, R.G, Pandha, H.S, Harrington, K.J

“…Summary Objective Oncolytic forms of attenuated Vaccinia virus are now in clinical development, assessing the compatibility of this novel treatment with…”
Get full text

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin–paclitaxel doublet chemotherapy by Roulstone, V, Twigger, K, Zaidi, S, Pencavel, T, Kyula, J N, White, C, McLaughlin, M, Seth, R, Karapanagiotou, E M, Mansfield, D, Coffey, M, Nuovo, G, Vile, R G, Pandha, H S, Melcher, A A, Harrington, K J

“…Oncolytic reovirus is currently under active investigation in a range of tumour types. Early phase studies have shown that this agent has modest monotherapy…”
Get full text

Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer by CLARK, C. H, MILES, E. A, GUERRERO URBANO, M. T, BHIDE, S. A, BIDMEAD, A. M, HARRINGTON, K. J, NUTTING, C. M

“…The purpose of this study was to compare conventional radiotherapy with parotid gland-sparing intensity-modulated radiation therapy (IMRT) using the PARSPORT…”
Get full text

Equivalence of cisplatin and carboplatin-based chemoradiation for locally advanced squamous cell carcinoma of the head and neck: A matched-pair analysis by Wilkins, A.C, Rosenfelder, N, Schick, U, Gupta, S, Thway, K, Nutting, C.M, Harrington, K.J, Newbold, K, Bhide, S.A

“…Summary Background Carboplatin can be substituted for cisplatin in concomitant chemoradiation (CRT) for locally advanced squamous cell carcinoma of the head…”
Get full text